

Implication on the EUL of Covid 19 vaccines after PHEIC was declared over

Following the announcement by Director General, of the termination of the PHEIC on 5 May 2023, the implications for Covid 19 vaccines listed under EUL, under evaluation or EOI submitted are the following:

1. The EUL status of currently listed vaccines will be maintained for a limited period of time while the product transitions to PQ and if the product continues to be supplied to LMICs.
2. EUL assessment of ongoing Covid 19 vaccines will be terminated unless the assessment is almost finalized. In this case the vaccine will receive EUL recommendation.
3. Expression of interests submitted for assessment under EUL, which have not been accepted for assessment, or new vaccines developed in the near future need to be submitted for PQ.

Further details will be communicated to manufacturers that have submitted an EOI (ongoing assessment or EOI submitted)

Manufacturers of vaccines with EUL recommendation, or under assessment, need to submit an application for PQ within 6 months of the termination of the PHEIC, in any case not later than 31 December 2023.